Short Interest Rises Across the Board in Major Biotechs

Health and Healthcare

Published: February 25, 2016 8:46 am

Last Updated: January 13, 2020 12:44 pm

The short interest data are out for the February 12 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.

The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected stocks for this settlement date.

Amgen Inc. (NASDAQ: AMGN) saw its short interest rise slightly to 10.63 million shares from the previous level of 10.41 million. Shares closed most recently at $147.11, in a 52-week trading range of $130.09 to $181.81.

Biogen Inc. (NASDAQ: BIIB) had its short interest increase to 3.37 million from the previous level of 2.76 million. Shares closed Wednesday at $257.22, within a 52-week range of $242.07 to $480.18.